One researcher, one sorter, one cell, many discoveries. BD is dedicated to developing easy-to-use cell sorting technologies that simplify accurate and reliable flow cytometry.
Established in 2013, Polpharma Biologics is the biotechnology unit of the rapidly growing Polpharma Group one of the largest pharmaceutical players in the CEE region. Currently, with over 140 people, four sites, and full expertise for biopharmaceutical development and production, Polpharma Biologics is running five projects dedicated to monoclonal antibodies, and is just stepping into the contract development and manufacturing business.
Pharmalink AB has hired Renee Aguiar-Lucander as Chief Executive Officer. She will lead the expansion and strategic development of the Swedish specialty pharmaceutical company following the clinical success of its orphan drug Nefecon.
German Merck KGaA has secured an option on UKs F-Star Biotechnology Ltds preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage.
Cambridge-based specialist ion channel CRO and drug discovery company Metrion Biosciences Ltd has named James Beaumont Head of Business Development. He joins from NZP-Dextra, where he held the post of Development Director.
Cambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties.
UK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch release to a location established in the Union.